Vanadyl-poly(γ-glutamic acid) complexes as oral therapeutic agents for the treatment of type 1 like diabetic mice

African Journal of Pharmacy and Pharmacology

Volumn 4, Issue 5, 2010, Pages 235-243

  Karmaker, Subarna ^a,b   Saha, Tapan K ^a,b   Yoshikawa, Yutaka ^b   Sakurai, Hiromu ^b  

^a JAHANGIRNAGAR UNIVERSITY   (Bangladesh)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Diabetes; Drug delivery system; Hyperglycemia; STZ mice; Vanadyl poly( glutamic acid) complex

Indexed keywords

ADRENALIN; HEMOGLOBIN A1C; UNCLASSIFIED DRUG; VANADIUM DERIVATIVE; VANADYL POLYGLUTAMIC ACID COMPLEX; VANADYL SULFATE;

ADIPOCYTE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG BONE LEVEL; DRUG BRAIN LEVEL; DRUG LIVER LEVEL; DRUG MUSCLE LEVEL; DRUG TISSUE LEVEL; FATTY ACID BLOOD LEVEL; GLYCEMIC CONTROL; HEART; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY; LUNG; MALE; METABOLIC SYNDROME X; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PANCREAS; RAT; SPLEEN; STREPTOZOCIN DIABETES; TISSUE DISTRIBUTION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77954665434     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Adachi Y, Yoshida J, Kodera Y, Katoh A, Takada J, Sakurai H (2006). Bis (allixinato) oxovanadium(IV) Complex Is a Potent Antidiabetic Agent: Studies on Structure-Activity Relationship for a Series of Hydroxypyrone-Vanadium Complexes. J. Med. Chem. 49(11): 3251-3256.
2. Chasteen ND (1981). In: Berliner L, Reuben J (Eds.), Biological Magnetic Resonance; Vol. 3; New York, Plenum. pp. 53-119.
3. Crans DC, Smee JJ, Gaidamauskas E, Yang L (2004). The Chemistry and Biochemistry of Vanadium and the Biological Activities Exerted by Vanadium Compounds. Chem. Rev. 104(2): 849-902.
4. Cusi K, Cukier S, Defronzo RA, Torres M, Puchulu FM, Redondo JCP (2001). Vanadyl Sulfate Improves Hepatic and Muscle Insulin Sensitivity in Type 2 Diabetes. J. Clin. Endocrinol. Metab. 86(3): 1410-1417.
5. Goldfine AB, Patti ME, Zuberi L, Goldstein BJ, LeBlane R, Landaker EJ, Jiang ZY, Willsky GR, Khan CR (2000). Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. Metabolism, 49(3): 400-410.
6. Groop LC (1992). Sulfonylureas in NIDDM. Diabetes Care, 15(6): 737-754.
7. Hansen TV, Aaseth J, Alexander J (1982). The effect of chelating agents on vanadium distribution in the rat body and on uptake by human erythrocytes. Arch. Toxicol. 50(3-4): 195-202.
8. Inzucchi SE (2002). Oral Antihyperglycemic Therapy for Type 2 Diabetes. J. Am. Med. Assoc. 287(3): 360-372.
9. Jandhyala BS, Hom GJ (1983). Physiological and pharmacological properties of vanadium. Life Sci. 33(14): 1325-1340.
10. Karmaker S, Saha TK (2008). Chelation of vanadium(IV) by natural and edible biopolymer poly-γ-glutamic acid in aqueous solution: Structure and binding constant of complex Macromol. Biosci. 8(2): 171-176.
11. Karmaker S, Saha TK, Sakurai H (2007). Investigation of Cu(II)-poly(γ-glutamic acid) complex in aqueous solution and its insulin-mimetic activity. Macromol. Biosci. 7(4): 456-466.
12. Karmaker S, Saha TK, Sakurai H (2008). Antidiabetic activity of the orally effective vanadyl-poly(γ-glutamic acid) complex in streptozotocin(STZ)-induced type 1 diabetic mice. J. Biomater. Appl. 22(5): 449-464.
13. y mice by poly (γ-glutamic acid) oxovanadium (IV) complex. Chem. Med. Chem. 2(11): 1607-1612.
14. Karmaker S, Saha TK, Yoshikawa Y, Yasui H, Sakurai H (2006). A novel drug delivery system for type 1 diabetes: insulin-mimetic vanadyl-poly(γ-glutamic acid) complex. J. Inorg. Biochem. 100(9): 1535-1546.
15. Karter AJ, Moffet HH, Liu J, Parker MM, Ahmed AA, Ferrara T, Selby JV (2005). Achieving Good Glycemic Control: Initiation of New Antihyperglycemic Therapies in Patients with Type 2 Diabetes From the Kaiser Permanente Northern California Diabetes Registry. Am. J. Manag. Care, 11(4): 262-270.
16. Kawabe K, Yoshikawa Y, Adachi Y, Sakurai H (2006). Possible mode of action for insulinomimetic activity of vanadyl(IV) compounds in adipocytes. Life Sci. 78(24): 2860-2866.
17. Koenig RJ, Peterson CM, Kilo C, Cerami A, Williamson JR (1976). Hemoglobin AIc as an indicator of the degree of glucose intolerance in diabetes. Diabetes, 25(3): 230-232.
18. Mehdi MZ, Pandey SK, Theberge JF, Srivastava AK (2006). Insulin Signal Mimicry as a Mechanism for the Insulin-Like Effects of Vanadium. Cell Biochem. Biophys. 44(1): 73-82.
19. Nakai M, Watanabe H, Fujiwara C, Kakegawa H, Satoh T, Takeda J, Matushita R, Sakurai H (1995). Mechanism on Insulin-like Action of Vanadyl Sulfate: Studies on Interaction between Rat Adipocytes and Vanadium Compounds. Biol. Pharm. Bull. 18 (5): 719-725.
20. Quraishi I, Collins S, Pestaner JP, Harris T, Bagasra O (2005). Role of zinc and zinc transporters in the molecular pathogenesis of diabetes mellitus. Med. Hypoth. 65(5): 887-892.
21. Rangel M, Tamura A, Fukushima C, Sakurai H (2001). In vitro study of the insulin-like action of vanadyl-pyrone and -pyridinone complexes with a VO(O4) coordination mode. J. Biol. Inorg. Chem. 6(2): 128-132.
22. Rehder D (2003). Biological and medicinal aspects of vanadium. Inorg. Chem. Commun. 6(5): 604-617.
23. Robin S, Kumar V, Cotran S (2003). Basic Pathology, Lippincot Publication: New York. p. 621.
24. y mice. J. Pharm. Pharmacol. 59(3): 437-444.
25. Saha TK, Yoshikawa Y, Yasui H, Sakurai H (2006). Oxovanadium(IV)- porphyrin complex as a potent insulin-mimetic: treatment of experimental type 1 diabetic mice by [meso-tetrakis(4-sulfonatophenyl)porphyrinato]oxovanadate(IV)(4-) complex. Bull. Chem. Soc. Jpn. 79(8): 1191-1200.
26. Saino-Oppermann FB, Steinbuchel A (2002). Occurrence, functions and biosynthesis of polyamides in microorganisms and biotechnological production. Naturwissenschaften, 89(1): 11-22.
27. Sakurai H, Tsuchiya K, Nukatsuka M, Kawada J, Ishikawa S, Yoshida H, Komatsu M (1990). Insulin-Mimetic Action of Vanadyl Complexes. J. Clin. Biochem. Nutr. 8(3): 193-200.
28. Shechter Y, Goldwaser I, Mironchik M, Fridkin M, Gefel D (2003). Historic perspective and recent developments on the insulin-like actions of vanadium; toward developing vanadium-based drugs for diabetes. Coord. Chem. Rev. 237(1-2): 3-11.
29. Shibuichi I, Yasue M, Kato K, Watanabe Y (2006). Consideration on the effects of natural water containing vanadium on diabetic mellitus. Biomed. Res. Trace Ele. 17(1): 11-16.
30. Sung MH, Park C, Kim CJ, Poo H, Soda K, Ashiuchi M (2005). Natural and edible biopolymer poly-γ-glutamic acid: synthesis, production and applications. Chem. Rec. 5(6): 352-366.
31. Thompson KH, Orvig C (2004). Vanadium Compounds in the Treatment of Diabetes. Met. Ions Biol. Syst. 41(7): 221-252.
32. Thompson KH, Orvig C (2006). Vanadium in diabetes: 100 years from Phase 0 to Phase 1. J. Inorg. Biochem. 100(12): 1925-1935.
33. Wysowski DK, Armstrong G, Governale L (2003). Rapid Increase in the Use of Oral Antidiabetic Drugs in the United States. Diabetes Care 26(6): 1852-1855.
34. Yasui H, Tamura A, Takino T, Sakurai H (2002). Structure-dependent metallokinetics of antidiabetic vanadyl-picolinate complexes in rats: Studies on solution structure, insulinomimetic activity and metallokinetics. J. Inorg. Biochem. 91(1): 327-338.